Soleno Therapeutics (SLNO) Asset Utilization Ratio (2015 - 2026)

Soleno Therapeutics (SLNO) posted quarterly Asset Utilization Ratio of 0.49 for Q1 2026, up 48.6% quarter-over-quarter from 0.33 in Q4 2025.

Soleno Therapeutics (SLNO) Asset Utilization Ratio (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has reported Asset Utilization Ratio for 5 consecutive years, with 0.49 the latest figure, recorded in Q1 2026.

In Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.49; the TTM figure through Mar 2026 stood at 0.49 (changed N/A YoY), while the FY2025 annual figure was 0.43, changed N/A from the prior year.
Asset Utilization Ratio climbed to 0.49 in Q1 2026 per SLNO's latest filing, from 0.33 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.49 in Q1 2026 and bottomed at 0.11 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.38
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.69
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	186.67
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.13
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.90
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.54
10	Soleno Therapeutics	2.74 Bn	2.49 Bn	93.41 Mn	0.49

Download Data